

#### **Mechanisms of Cartilage Damage**

#### Mary B. Goldring, PhD



Senior Scientist, Hospital for Special Surgery, New York, NY

Professor of Cell & Developmental Biology Weill Cornell Medical College & Weill Cornell Graduate Program of Medical Sciences



#### Osteoarthritis (OA)

•Most common cause of disabilities in older population

- > 20 million Americans affected by OA
- More than 900,000 joint replacements every year at a cost of \$42.3 million
- <u>Symptoms</u>: Pain and stiffness, swelling and tenderness
- <u>Radiographic signs</u>: joint space narrowing, osteophyte formation, bone marrow lesions
- <u>Treatment options</u>: Control of pain and inflammation, improvement of joint function, and ultimately surgery







## OA is a "joint" disorder

- OA is characterized by alterations in the composition, structural organization and functional properties of all of the joint tissues:
  - Cartilage
  - Calcified cartilage
  - Bone
  - Synovium
  - Ligaments, menisci, tendons






- The alterations are mediated via mechanical damage (disruption) and cellular mechanisms that modify the composition, structure and properties of the tissues.
- Alterations in a single tissue eventually will adversely affect all of the joint tissues




## Cartilage & Osteoarthritis



Patella Posterior cruciate

The complexity of the composition and cellular organization of articular cartilage presents a tissue engineering challenge for developing repair strategies
Successful therapies must prevent damage or promote repair to recapitulate the physiological and functional properties of cartilage.





Heinegard & Saxne: Nature Rev Rheumatol 7:50-56, 2011

## Evidence of adaptive capacity of articular cartilage

## Effect of loading on cartilage deformation behavior and metabolism

- <u>Methods</u>: evaluated the effect of running (30 min) and drop landing on knee cartilage deformation using MRI and serum COMP levels
- <u>Results</u>: Serum COMP levels increased immediately after running and drop landing. Cartilage deformation was more pronounced after running than drop landing
- <u>Conclusion</u>: In vivo exercise modulates cartilage morphology and the metabolic activity of chondrocytes






www.photo-dictionary.com




Niehoff A et al. Osteoarthritis Cartilage 2011; 19:1003-10

## Adaptation of chondrocytes to physiological mechanical loading



## **Physiological mechanical loading**




Maintenance and/or restoration of composition and structural and function properties of the tissue matrix



# How do chondrocytes sense their mechanical environment?

- Ion channels (Trpv4)
- Integrin-mediated
- Cytoskeletal deformation
- Fluid flow

Guilak F. Best Pract Res Clin Rheumatol. 2012; 25:815-23



Compression-induced gene expression modulation (fold change)


Bougault c et al. PloS One. 2012; 7(5)e36964

Implications: Targeting mechanosensors represents a rationale approach for OA therapy

HOSPITAL FOR SPECIAL SURGERY

#### Mechanism of joint "lubrication": Role of Iubricin

 The cartilage surface is uniquely adapted to transfer of loads (exhibits a unique low friction property of orders of magnitude less than ice)






#### Role of *lubricin* in cartilage homeostasis

- <u>Lubricin</u> is a product of the *PRG4 gene* that is produced by superficial articular chondrocytes and synovial lining cells
- Loss of function mutations in *PRG4* causes camptodactyly-arthropathy coxa vera-pericarditis syndrome, which is associated with early OA
  - Marcelino et al. Nat Genet 1999; 23:319-22
- Genetic knockout of *Prg4* in mice results in OA pathology
  - Rhee et al. J Clin Invest 2005; 115:622-31
- Lubricin provides synovial fluid its capacity to dissipate energy under load; and is chondroprotective in *Prg4* knockout mice and in a rat OA model
  - Gleghorn, Bonassar et al. J Orthop Res 2009; 27:771-7
  - Flannery, Bonassar et al. Arthritis Rheum 2009; 60:840-47
- Forced PRG4 expression protects against the development of OA
  - Ruan, Lee et al. Sci Transl Med. 2013 Mar 13;5(176):176ra34

#### Michelangelo's David: the late years



Could it have been prevented or treated?

FOR

SPECIA


#### Age-associated changes in chondrocytes

- Altered pattern of matrix synthesis
- Increased production of matrix degrading enzymes
- Increased apoptosis (programmed cell death)
- Decreased capacity to handle stress
  - Changes in sensitivity to growth factors
  - Altered proliferative capacity

Loeser et al. Arthritis Rheum. 2012; 64:1697-1707



#### Macroscopic and Histological Appearance of Human Articular Cartilage




Young normal

Old normal OA Lotz M & Loeser RF: Bone 2012



#### Effect of extent of joint injury on natural history of OA




#### Time (years)


Murrell et al. Am J Sports Med. 2001; 29:9-14 Maffulli et al. J Arthroscopic Rel Res. 2003; 19:685-90 Lohmander et al. Am J Sports Med 2007; 35:1356-79




### Distribution of contact forces in the knee




Provided by: S. Maher PhD. HSS




### Meniscal tear disrupts contact forces



Excessive mechanical loading leads to irreversible dysregulation of chondrocyte function



## **Mechanical injury**



Restoration of composition and structural and function properties of the tissue matrix

> Instability Incongruity Inflammation ECM alterations Cell de-regulation


#### OA is associated with a chondrocyte "catabolic state"

#### Decreased aggrecan content


- -decreased synthesis
- -increased breakdown
- Alterations in patterns of collagens synthesized
  - -Switch from type II collagen to types I and X
- Production of matrix degradation products
   -DAMPs, alarmins
- Decreased expression of or response to anabolic growth factors
  - -IGF-1, TGF- $\beta$ , etc.
- Up-regulation of proteases
  - -MMPs, aggrecanases, cathepsins
- Production of proinflammatory mediators/cytokines
  - -IL-1, IL-6, IL-8, MCP-1, VEGF, reactive oxygen species, nitric oxide, prostaglandins

Heinegard. Int J Exp Path 2009; 90:575-86 Maldonado and Nam. Biomed Res Int 2013:28483





#### From homeostasis to osteoarthritis



Loeser et al. Arthritis Rheum 2012; 64: 1697-1707

#### Structural organization of the osteochondral unit





Diagram of the bone surface with noncalcified cartilage cut away to reveal the calcified cartilage. (Reprinted from Bullough and Jagannath, 1983<sup>13</sup>, with permission from The British Editorial Society of Bone and Joint Surgery, London, UK.)




## Molecular cross-talk at the osteochondral junction



Suri S, Walsh DA. Bone 2012;51(2):204-11

## Structure of the normal knee joint and the osteochondral unit and changes in late-stage OA



Goldring & Goldring: Nature Rev Rheumatol 2016

#### OA pathogenesis: Current View

- Complexity of normal cartilage matrix and inadequate repair mechanisms makes it difficult to reverse cartilage damage once OA progresses
- Matrix metalloproteinase, MMP-13 has a pivotal role in OA progression as the collagenase that preferentially degrades type II collagen, but its inhibition does not block all aspects of pathogenesis.
- Similar signaling pathways and downstream transcriptional regulators are induced by inflammatory, mechanical, and oxidative stresses.
- The heterogeneity of OA phenotypes, represented in different in vitro and in vivo models, demonstrate common mechanisms over the time course of initiation and progression but present challenges for therapeutic development.



## **Goals of OA Therapy**

- Make diagnosis early before significant structural damage and symptomatic and functional impairment
- Control symptoms and maintain function
- Prevent progression
- Monitor clinical course and treatment response
- Minimize adverse therapeutic side effects

Modified from OARSI recommendations for the management of hip and knee OA Zhang W et al. Osteoarthritis and Cartilage. 2008. 16: 137-162

**Bottom line:** There isno approved pharmacologic therapy that has been shown to prevent the development or progression of OA.



## Pharmacologic (Symptomatic) treatment of OA

#### Oral

- Acetomenophen
- NSAIDs
- COX-specific inhibitors
- Glucosamine/chondroitin sulfate

#### Intraarticular

- Glucocorticoids
- Hyaluronan
- Platelet Rich Plasma (PRP)
- Topical
  - Capsaicin
  - Methylsalicylate



### Heterogeneity of OA

Joint Injury Inflammation Causative Meniscus Genetics Repetitive Injury **Factors** ACL Subchondral Bone Aging Changés Disease  $\longrightarrow$  Advanced OA Initiation → Early OA Progression Proteolytic enzyme production Structural Matrix degradation And Cellular Release of matrix fragments

Changes

Cytokine Production



# **Cpnclusions: OA as a therapeutic challenge**

- OA is not a homogeneous disorder.
- The pathogenic mechanisms differ among individuals.
- In the same individual, pathogenic mechanisms and processes may differ at specific stages of disease initiation and progression.
- Knock out of a number of different genes can decrease OA development in mouse models. Therefore, it is difficult to determine which mechanisms to target for therapy.
- The design of clinical trials with selection of cohorts based on risk factors may lead to more rational approaches to therapy targeting disease initiation and progression.





#### Acknowledgements: Collaborators

- NIH-R01-AG022021: "ESE1 a novel transcriptional regulator of cartilage remodeling"
- NIH-RC4 AR060546: "Defining Common Molecular Parameters for Onset and Progression of Osteoarthritis"
  - Kenneth B. Marcu (Stony Brook University)
  - Yefu Li (Harvard Medical School)
  - Roland Wolkowicz (San Diego State Univ)
- NIH-R21 AR054887: "Epigenetic Regulation of MMP-13"
  - Ko Hashimoto (Tohoku Univ, Sendai, Japan)
  - Richard Oreffo (Trudy Roach), et al. (Univ of Southampton)
    - Supported by the



- NIH-R21-AR064034-01A1: Marjolein van der Meulen (Cornell Univ) :: "Role of Cartilage Matrix in a model of load-induced OA"
- Carl Blobel (HSS): Arthritis Foundation IRG-6353: "Role of iRhom2 and ADAM17 in osteoarthritis"
- Eleonora Olivotto
  - University of Bologna
- Marta Favero
  - University of Padova

